Weichun Xu
About
Weichun Xu is a scholar working on Rheumatology, Hematology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Weichun Xu has authored 33 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Rheumatology, 9 papers in Hematology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Weichun Xu's work include Rheumatoid Arthritis Research and Therapies (12 papers), Autoimmune and Inflammatory Disorders Research (9 papers) and Spondyloarthritis Studies and Treatments (6 papers). Weichun Xu is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (12 papers), Autoimmune and Inflammatory Disorders Research (9 papers) and Spondyloarthritis Studies and Treatments (6 papers). Weichun Xu collaborates with scholars based in United States, United Kingdom and Canada. Weichun Xu's co-authors include Mahboob U. Rahman, Désirée van der Heijde, Joyce A. Cramer, Dennis S. Charney, Robert A. Rosenheck, Sudha Visvanathan, Jonathan Thomas, Paul Williamson, William Henderson and Jürgen Braun and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and American Journal of Psychiatry.
In The Last Decade
Weichun Xu
33 papers receiving 2.6k citations
Peers
Weichun Xu
Corrado Bernasconi Switzerland
Kay E. Wellik United States
Kristina Unnebrink Germany
J O’Riordan United Kingdom
Johannes W G Jacobs Netherlands
John G. Hanly Canada
Sizheng Steven Zhao United Kingdom
Karen Schreiber Denmark
Chiara Tani Italy
S van der Linden Netherlands
Citations per year, relative to Weichun Xu Weichun Xu (= 1×)
peers
Corrado Bernasconi
Countries citing papers authored by Weichun Xu
Since
Specialization
Citations
This map shows the geographic impact of Weichun Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weichun Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weichun Xu more than expected).
Fields of papers citing papers by Weichun Xu
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Weichun Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weichun Xu. The network helps show where Weichun Xu may publish in the future.
Co-authorship network of co-authors of Weichun Xu
This figure shows the co-authorship network connecting the top 25 collaborators of Weichun Xu. A scholar is included among the top collaborators of Weichun Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weichun Xu. Weichun Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Calvo, Emiliano, Bernard Doger, Joan Carles, et al.. (2025). A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer. The Oncologist. 30(1).
2.
Yang, Bo, Yang Zhang, Shilong Wang, et al.. (2022). A global interactive attention-based lightweight denoising network for locating internal defects of CFRP laminates. Engineering Applications of Artificial Intelligence. 116. 105436–105436.
3.
Li, Jianping, Wenjie Lv, Jianqi Chen, et al.. (2022). Removal of chlorine, microparticles and water from high-viscosity liquids by a sand filter coupling hydrocyclone. Process Safety and Environmental Protection. 170. 636–646.
4.
Takeuchi, Tsutomu, Carter Thorne, George Karpouzas, et al.. (2017). Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. Annals of the Rheumatic Diseases. 76(12). 2001–2008.
5.
Wasko, Mary Chester, Elizabeth C. Hsia, Bruce Kirkham, et al.. (2013). Effect of Golimumab on Carotid Atherosclerotic Disease Measures and Cardiovascular Events in Inflammatory Arthritides. JCR Journal of Clinical Rheumatology. 20(1). 1–10.
6.
Kavanaugh, Arthur, Désirée van der Heijde, Iain B. McInnes, et al.. (2012). Golimumab in psoriatic arthritis: One‐year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo‐controlled trial. Arthritis & Rheumatism. 64(8). 2504–2517.
7.
Kavanaugh, Arthur, Iain B. McInnes, Philip J. Mease, et al.. (2012). Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Annals of the Rheumatic Diseases. 72(11). 1777–1785.
8.
Braun, Jürgen, Xenofon Baraliakos, Kay‐Geert Hermann, et al.. (2011). Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Annals of the Rheumatic Diseases. 71(6). 878–884.
9.
Østergaard, Mikkel, Paul Emery, Philip G. Conaghan, et al.. (2011). Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: A magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients. Arthritis & Rheumatism. 63(12). 3712–3722.
10.
Emery, Paul, Désirée van der Heijde, Mikkel Østergaard, et al.. (2011). Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 70(12). 2126–2130.
11.
Emery, Paul, Roy Fleischmann, Larry W. Moreland, et al.. (2009). Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis. Arthritis & Rheumatism. 60(8). 2272–2283.
12.
Heijde, Désirée van der, Robert Landewé, Xenofon Baraliakos, et al.. (2008). Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis & Rheumatism. 58(10). 3063–3070.
13.
Braun, Jürgen, Atul Deodhar, Ben A. C. Dijkmans, et al.. (2008). Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two‐year period. Arthritis Care & Research. 59(9). 1270–1278.
14.
Rosenheck, Robert A., Joyce A. Cramer, Deborah Perlick, et al.. (2000). Clinical and Psychopharmacologic Factors Influencing Family Burden in Refractory Schizophrenia. The Journal of Clinical Psychiatry. 61(9). 671–676.
15.
Rosenheck, Robert A., Sidney S. Chang, Yeon Hyeon Choe, et al.. (2000). Medication Continuation and Compliance. The Journal of Clinical Psychiatry. 61(5). 382–386.
16.
Hitsman, Brian, Regina Pingitore, Bonnie Spring, et al.. (1999). Antidepressant pharmacotherapy helps some cigarette smokers more than others.. Journal of Consulting and Clinical Psychology. 67(4). 547–554.
17.
Rosenheck, Robert, Lawrence A. Dunn, Michael Alfred Peszke, et al.. (1999). Impact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia. American Journal of Psychiatry. 156(1). 88–93.
18.
Rosenheck, Robert A., William Lawson, John W. Crayton, et al.. (1998). Predictors of differential response to clozapine and haloperidol. Biological Psychiatry. 44(6). 475–482.
19.
Rosenheck, Robert A., Joyce A. Cramer, Weichun Xu, et al.. (1997). A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia. New England Journal of Medicine. 337(12). 809–815.
20.
Green, Joseph B., et al.. (1997). The P1 Component of the Middle Latency Auditory Potential May Differentiate a Brainstem Subgroup of Alzheimer Disease. Alzheimer Disease & Associated Disorders. 11(3). 153–157.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Corrado Bernasconi Breakdown of academic impact, for papers by Kay E. Wellik Breakdown of academic impact, for papers by Kristina Unnebrink Breakdown of academic impact, for papers by J O’Riordan Breakdown of academic impact, for papers by Johannes W G Jacobs Breakdown of academic impact, for papers by John G. Hanly Breakdown of academic impact, for papers by Sizheng Steven Zhao Breakdown of academic impact, for papers by Karen Schreiber Breakdown of academic impact, for papers by Chiara Tani Breakdown of academic impact, for papers by S van der Linden